Drug development is a costly, time-intensive and high-risk endeavour, with only two to three approvals for novel therapeutics in new drug classes per year eventually making it to market. New ...

The “Magnificent Seven” are seven mega-cap, tech-heavy companies that have driven a huge share of U.S. stock market gains in recent years. They’re leaders in areas like AI, cloud computing, digital ...